New cocktail aims to shrink head and neck tumors before surgery
NCT ID NCT07457346
First seen Mar 19, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This phase 2 trial tests a new combination of drugs—imaxitinib, chemotherapy, and immunotherapy—given before surgery for advanced head and neck cancer. The goal is to see if this approach can shrink tumors more effectively, making surgery easier or possible for patients whose cancer is hard to remove. About 76 participants will receive the treatment and be monitored for tumor response and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imaxitinib (a JAK inhibitor) combined with chemotherapy (cisplatin, nab-paclitaxel) and immunotherapy (adebrelimab)
What this could lead to
If successful, this combination could shrink advanced head and neck tumors before surgery, potentially making surgery easier or possible for more patients.
What could go wrong
This is a small, early-phase trial (76 people) with no results yet. The drug combo may cause side effects or not work better than current treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.